This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Intravitreal Bevacizumab for Diabetic Macular Edema

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Isfahan Ophthalmology Research Center.
Recruitment status was:  Enrolling by invitation
Sponsor:
Information provided by:
Isfahan Ophthalmology Research Center
ClinicalTrials.gov Identifier:
NCT00703235
First received: June 20, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
June 20, 2008
June 20, 2008
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Intravitreal Bevacizumab for Diabetic Macular Edema
Not Provided

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Not Provided
Interventional
Phase 2
Phase 3
Not Provided
  • Macular Edema
  • Diabetic Retinopathy
Drug: Bevacizumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Diabetes mellitus
  • Clinically significant macular edema
  • Possibility of performing macular OCT
  • Consent of patient for inclusion in the study

Exclusion Criteria:

  • History of macular photocoagulation in less than 6 months of inclusion in the study
  • Necessity of surgical intervention
  • Rejection of the remaining in the study by patient
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00703235
MUI - clinical - 185290
Not Provided
Not Provided
Not Provided
Not Provided
Isfahan Ophthalmology Research Center
Not Provided
Not Provided
Isfahan Ophthalmology Research Center
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP